Vor Biopharma (VOR) Gains from Investment Securities (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Gains from Investment Securities data on file, last reported at $2000.0 in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $2000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 456265.61% YoY), and the FY2025 annual result was $6.6 million, up 1345.53% from the prior year.
• Gains from Investment Securities slipped to $2000.0 in Q1 2026 per VOR's latest filing, from $148000.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $1.3 billion in Q2 2025 and troughed at -$831000.0 in Q4 2022.
• A 5-year average of $94.4 million and a median of $1.7 million in 2022 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities soared 1514.7% in 2022, then tumbled 124.78% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at -$831000.0 in 2022, then soared by 238.39% to $1.2 million in 2023, then tumbled by 124.78% to -$285000.0 in 2024, then soared by 151.93% to $148000.0 in 2025, then plunged by 98.65% to $2000.0 in 2026.
• Business Quant data shows VOR's Gains from Investment Securities at $2000.0 in Q1 2026, $148000.0 in Q4 2025, and $5.2 million in Q3 2025.